治疗地理缩患者:我们已经到达了吗?
Bani Antonio-Aguirre1, J Fernando Arevalo2
1Wilmer Eye Institute, Johns Hopkins School of Medicine, 600 N Wolfe St; Maumenee 713, Baltimore, MD, 21287, USA.
International journal of retina and vitreous
|November 21, 2023
概括
地理缩 (GA) 是老年人视力丧失的主要原因. 最近的进展包括第一个FDA批准的治疗方法,佩格塞塔科普兰,为管理这种复杂的疾病提供了新的希望.
科学领域:
- 眼科医生 眼科 眼科
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 地理缩 (GA) 是一种渐进的退行性疾病,在50岁以上的人群中引起显著的视力损伤.
- 风险因素包括年龄,吸烟和遗传变异,特别是影响补体系统调节者的遗传变异.
研究的目的:
- 提供地理缩 (GA) 的全面审查.
- 涵盖风险因素,患病率,遗传关联和成像特征.
- 讨论目前和新兴的GA治疗方法,包括未来的考虑.
主要方法:
- 对地理缩现有研究的文献综述.
- 分析当前的治疗方式,包括已批准的疗法和临床试验.
- 检查与GA发展相关的遗传和风险因素数据.
主要成果:
- 补充C3抑制剂Pegcetacoplan是第一个FDA批准的GA治疗方法.
- 许多其他干预措施都处于II或III期临床试验中.
- 了解个体风险因素和遗传特征对于治疗选择至关重要.
结论:
- 该审查强调了GA治疗的重大进展,个性化医疗方法变得越来越重要.
- 确定适合特定疗法的候选者和监测长期结果是未来的关键方向.
- 新兴的治疗方法有望改善GA患者的视觉功能和生活质量.
更多相关视频
11:03Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy
Published on: January 22, 2018
10.0K
12:56Methodology for Biomimetic Chemical Neuromodulation of Rat Retinas with the Neurotransmitter Glutamate In Vitro
Published on: December 19, 2017
7.8K
相关概念视频
Open Angle Glaucoma: Treatment
458
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
458
Alzheimer's Disease: Treatment
196
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
196
Angle Closure Glaucoma: Treatment
528
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
528
Myasthenia Gravis: Overview and Treatment
1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Parkinson's Disease: Treatment
278
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
278
